Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway

被引：1
|
作者：
Ravi, Gayathri [1 ]
Giri, Smith [2 ]
Bal, Susan [3 ]
Godby, Kelly N. [4 ]
Reddy, Vishnu V. B. [5 ]
Salzman, Donna [6 ]
Alkharabsheh, Omar [7 ]
McDaniel, Scott A. [8 ]
Sentell, Melissa [6 ]
Costa, Luciano J. [9 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Inst Canc Outcomes & Survivorship, Birmingham, AL USA
[3] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[4] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham Hosp, Birmingham, AL USA
[5] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[6] Univ Alabama Birmingham, Birmingham, AL USA
[7] Univ S Alabama, Mitchell Canc Inst, Mobile, AL USA
[8] Alabama Oncol Hematol Associates, Montgomery, AL USA
[9] Univ Alabama, Birmingham Hosp, Vestavia, AL USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170099
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8048 / 8049
页数：2
相关论文
共 50 条
  • [31] Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma
    Seval, Guldane Cengiz
    Dalva, Klara
    Bakanay, Sule Mine
    Soydan, Ender
    Ilhan, Osman
    Beksac, Meral
    Sonmez, Gulcin Miyase
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S108 - S108
  • [32] The association between minimal residual disease status and survival outcomes in transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients: Systematic review.
    Shah, Zunairah
    Khan, Israr
    Selene, Insija Ilyas
    Bin Waqar, Syed Hamza
    Khanam, Razwana
    Abid, Qurratul-Ain
    Tahir, Nayha
    Sathe, Sanjivani
    Laek, Babray
    Chattaraj, Asmi
    Roksana, Zinath
    Badu, Irisha
    Anwer, Faiz
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Efficacy of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.
    Avet-Loiseau, Herve
    Moreau, Philippe
    Attal, Michel
    Hulin, Cyrille
    Arnulf, Bertrand
    Corre, Jill
    Garderet, Laurent
    Karlin, Lionel
    Lambert, Jerome
    Macro, Margaret
    Perrot, Aurore
    Sonneveld, Pieter
    Levin, Mark-David
    Klein, Saskia
    Chiu, Christopher
    Pei, Lixia
    De Boer, Carla
    Kampfenkel, Tobias
    Wuilleme, Soraya
    Bene, Marie-Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)
    Jasielec, Jagoda
    Dytfeld, Dominik
    Griffith, Kent A.
    McDonnell, Kathryn
    Lebovic, Daniel
    Kandarpa, Malathi
    Anderson, Tara
    Mietzel, Melissa
    Faham, Malek
    Lee, Liana
    Levy, Joan
    Alonge, Mattina
    Rosebeck, Shaun
    Kaminski, Mark
    Jakubowiak, Andrzej
    BLOOD, 2014, 124 (21)
  • [35] Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).
    Derman, Benjamin Avi
    Zonder, Jeffrey A.
    Kansagra, Ankit J.
    Grinblatt, David L.
    Narula, Sunil
    Rayani, Shayan
    Stefka, Andrew T.
    Jiang, Ken
    Major, Sarah
    Wolfe, Brittany
    Whelan, Megan
    Libao, Bernadette
    McIver, Amanda
    Andreatos, Evangelia
    Juergens, Daniel
    Alcantar, Luis
    Karrison, Theodore
    Bishop, Michael Russell
    Jasielec, Jagoda
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center
    Blanco, Alberto
    Chari, Ajai
    Martin, Thomas G.
    Arora, Shagun
    Chung, Alfred
    Kumar, Anupama Deepa
    Shah, Nina
    Wong, Sandy W.
    Takamatsu, Hiroyuki
    Martinez-Lopez, Joaquin
    Wolf, Jeffrey Lee
    BLOOD, 2024, 144 : 7020 - 7021
  • [37] Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study
    Groen, Kaz
    Stege, Claudia A. M.
    Nasserinejad, Kazem
    de Heer, Koen
    Van Kampen, Roel J. W.
    Leijs, Maria B. L.
    Thielen, Noortje
    Westerman, Matthijs
    Wu, Ka Lung
    Ludwig, Inge
    Issa, Djamila
    Velders, Gerjo A.
    Vekemans, Marie-Christiane
    van de Donk, Niels W. C. J.
    Timmers, Gert-Jan
    Sonneveld, Pieter
    Seefat, Maarten R.
    Croon-de Boer, Fransien
    Tick, Lidwine W.
    van der Spek, Ellen
    De Waal, Esther G. M.
    Sohne, Maaike
    Ypma, Paula F.
    Nijhof, Inger S.
    Klein, Saskia K.
    Levin, Mark-David
    Zweegman, Sonja
    BLOOD, 2021, 138
  • [38] Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance
    Sweiss, Karen
    Hofmeister, Craig C.
    Zappia, Maria
    Frolov, Maxim
    Benevolenskaya, Elizaveta
    Quigley, John G.
    Kadkol, Shrihari
    Sborov, Douglas W.
    Rondelli, Damiano
    Patel, Pritesh
    BLOOD, 2022, 140 : 7304 - 7305
  • [39] Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
    Chhabra, Saurabh
    Callander, Natalie
    Watts, Nicole L.
    Costa, Luciano J.
    Thapa, Bicky
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Anderson, Larry D., Jr.
    Bal, Susan
    Dhakal, Binod
    Nathwani, Nitya
    Shah, Nina
    Medvedova, Eva
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Schmidt, Timothy
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Dholaria, Bhagirathbhai
    Cornell, R. Frank
    Jerkins, James H.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Usmani, Saad Z.
    Richardson, Paul G.
    Voorhees, Peter M.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (03): : 174e1 - 174e10
  • [40] Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study
    Shah, Nina D.
    Lutska, Yana
    Pei, Huiling
    Qi, Ming
    Krevvata, Maria
    Kane, Colleen
    Ukropec, Jon
    Lin, Thomas S.
    Hampras, Shalaka
    BLOOD, 2019, 134
12345